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Cultures of stem cells from discarded sources supplemented with dexamethasone, a
synthetic glucocorticoid receptor agonist, generate cultured red blood cells (cRBCs) in
numbers sufficient for transfusion. According to the literature, however, erythroblasts
generated with dexamethasone exhibit low enucleation rates giving rise to cRBCs that
survive poorly in vivo. The knowledge that the glucocorticoid receptor regulates lipid
metabolism and that lipid composition dictates the fragility of the plasma membrane
suggests that insufficient lipid bioavailability restrains generation of cRBCs. To test
this hypothesis, we first compared the expression profiling of erythroblasts generated
with or without dexamethasone. This analysis revealed differences in expression
of 55 genes, 6 of which encoding proteins involved in lipid metabolism. These
were represented by genes encoding the mitochondrial proteins 3-Hydroxymethyl-3-
Methylglutaryl-CoA lyase, upregulated, and 3-Oxoacid CoA-Transferase1 and glycerol-
3-phosphate acyltransferase1, both downregulated, and the proteins ATP-binding
cassette transporter1 and Hydroxysteroid-17-Beta-Dehydrogenase7, upregulated, and
cAMP-dependent protein kinase catalytic subunit beta, downregulated. This profiling
predicts that dexamethasone, possibly by interfering with mitochondrial functions,
impairs the intrinsic lipid metabolism making the synthesis of the plasma membrane
of erythroid cells depend on lipid-uptake from external sources. Optical and electron
microscopy analyses confirmed that the mitochondria of erythroblasts generated with
dexamethasone are abnormal and that their plasma membranes present pebbles
associated with membrane ruptures releasing exosomes and micro-vesicles. These
results indicate that the lipid supplements of media currently available are not adequate
for cRBCs. To identify better lipid supplements, we determined the number of
erythroblasts generated in synthetic media supplemented with either currently used
liposomes or with lipoproteins purified from human plasma [the total lipoprotein fraction
(TL) or its high (HDL), low (LDL) and very low (VLDL) density lipoprotein components].
Both LDL and VLDL generated numbers of erythroid cells 3-2-fold greater than that
observed in controls. These greater numbers were associated with 2–3-fold greater
Frontiers in Physiology | www.frontiersin.org 1 April 2019 | Volume 10 | Article 281
fphys-10-00281 April 2, 2019 Time: 19:56 # 2
Zingariello et al. Lipid Metabolism in Erythroid Cells
amplification of erythroid cells due both to increased proliferation and to resistance
to stress-induced death. In conclusion, dexamethasone impairs lipid metabolism
making ex vivo expansion of erythroid cells highly dependent on lipid absorbed from
external sources and the use of LDL and VLDL as lipid supplements improves the
generation of cRBCs.
Keywords: erythropoiesis, lipid metabolism, dexamethasone, ex vivo expansion, transfusion products
INTRODUCTION
The progress recently made in the development of culture
conditions that allow generating great numbers of cultured
red blood cells (cRBCs) from discarded stem cell sources is
prompting numerous studies aimed to validate these cells as
alternative transfusion products (Anstee et al., 2012; Bouhassira,
2012; Migliaccio et al., 2012). Several investigators are currently
addressing the numerous challenges encountered in bringing
cRBCs into the clinic. The proof-of-principle in animal models
was provided in 2008 by the Nakamura laboratory which
indicated that transfusion of ex vivo generated erythroblasts
protects mice from lethal hemolytic anemia (Hiroyama et al.,
2008). Giarratana et al. (2011) provided the first proof-of-concept
in man by demonstrating that autologous cRBCs generated
from mobilized CD34pos cells survive for approximately 30 days
in vivo. The Douay study also defined good manufacturing
practice (GMP) conditions and minimal safety criteria of cRBCs
for transfusion (Giarratana et al., 2011; Clinicaltrials.gov, 2012).
Additional steps forward were represented by the demonstration
that these cells express normal levels of blood group antigens
and remain viable after cryopreservation for at least 8 years.
Furthermore, these cells may also be generated from discarded
buffy coats from blood donations with rare blood phenotypes
collected under GMP conditions using media composed by
clinical grade reagents of human origin and may be exchanged
among laboratories across countries without loss of viability
(reviewed in Zeuner et al., 2012).
The development of culture conditions allowing generating
great numbers of cRBCs was pioneered by Dr. Fibach who
was the first to divide the cultures into two phases (Fibach
et al., 1989): the first phase (proliferation) induces hematopoietic
stem/progenitor cells to generate morphologically recognizable
erythroblasts; the second phase maturation sustains terminal
maturation and enucleation generating cRBCs. The two phases
are promoted by two different sets of stimuli. In the first
phase, the signaling supporting more efficiently proliferation
mimics stress erythropoiesis. These conditions were devised by
exploiting the knowledge that, in vivo, recovery from acute
anemia requires activation of the stress pathway controlled
by the glucocorticoid receptor that confers to erythroid
progenitors the ability to self-replicate (von Lindern et al.,
1999; Dolznig et al., 2006; Zhang et al., 2013). Cultures
that mimic the stress pathway are therefore stimulated with
hematopoietic cytokines (stem cell factor, SCF; interleukin-3,
IL-3; and erythropoietin, EPO) in combination with synthetic
agonists of the glucocorticoid receptor (either hydrocortisone
or dexamethasone, Dex) (Migliaccio et al., 2002; Giarratana
et al., 2005; Leberbauer et al., 2005). Maturation is scanty in
proliferation cultures. To promote maturation, cells generated
after 12–15 days of proliferation cultures are transferred to
the second phase culture stimulated with EPO where the cells
mature in 7–10 days.
For reasons only partially known, erythroblasts generated
with Dex mature in great numbers in vivo when transfused
into immune-deficient hosts but enucleate with low efficiency
when transferred in maturation cultures (Neildez-Nguyen et al.,
2002). This challenge was first addressed by the discovery that
maturation of erythroblasts into cRBCs is greatly improved
by the presence of a feeder layer (Neildez-Nguyen et al.,
2002). Since the feeder cells are often of animal original, these
conditions are poorly suited for production of clinical grade
products. Following studies discovered that feeder cells may be
replaced by mifepristone, an antagonist of the glucocorticoid
receptor, and plasmanate, a clinical grade derivative of human
plasma (Miharada et al., 2006). In addition, enucleation rates
may be further improved, reaching approximately 90%, by
supplementing the maturation cultures with unfractionated
human plasma and thyroid hormone (van den Akker et al., 2010;
Masiello et al., 2013). These observations suggest that enucleation
in vitro is promoted by inhibition of the glucocorticoid receptor
signaling, activation of signaling from the thyroid hormone
receptor and by components still to be identified present in
human plasma. While genetic studies in mice have clarified
that the thyroid hormone receptor exerts a pivotal role in the
regulation of terminal erythroid maturation (Tanabe et al., 2007),
the roles exerted in this process by the glucocorticoid receptor
and by human plasma are still poorly understood.
The observation that survival of cRBCs in vivo (30 days) is
inferior to that expected for young cells (120 days) (Giarratana
et al., 2011) suggests that even under the best enucleation
conditions developed up to now, cRBCs are fragile. Since the
fragility of RBCs is greatly dependent on the physical-chemical
properties of their plasma membrane, including fluidity, which
are in turn regulated by its lipid composition (Brewer, 1980; An
and Mohandas, 2008; Pollet et al., 2018), we hypothesized that
the presence of Dex impairs the lipid metabolism of erythroid
cells making the biosynthesis of their membranes extremely
dependent on lipid uptake from lipoproteins present in human
plasma and supplemented in the culture medium.
The plasma membrane of erythroid cells, as that of all the other
cell types, consists of a lipid-bilayer attached to the cytoskeleton
by integral membrane proteins (Mohandas and Gallagher, 2008).
Approximately half of the mass of a RBC is represented by
lipids (primarily phospholipids and non-esterified cholesterol)
the balanced composition of which has been demonstrated to
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confer resistance to sheer stress in the circulation (Brewer, 1980;
An and Mohandas, 2008; Pollet et al., 2018). In vivo, erythroblasts
obtain their lipids either by biosynthesis or by absorption from
their natural carriers, the circulating lipoproteins, present in
plasma (van den Broek et al., 2017). In culture, erythroblasts
may synthesize their lipids from fatty acids carried by albumin
and absorb lipids by uptake either from lipoproteins present in
fetal bovine serum (FBS) or from synthetic liposomes composed
by bovine or human albumin, egg cholesterol and soybean
lecithin (Migliaccio and Migliaccio, 1987). Therefore, the lipid
composition, and integrity, of the plasma membrane of cultured
erythroblasts depends both on the efficiency of the intrinsic cell
biosynthetic pathways of the cell and on the presence in the media
of lipid carriers suited for optimal absorption (Huang et al., 2018).
To a surprise, in spite of the well-established effects exerted by
glucocorticoids on lipid metabolism in other systems (Patel et al.,
2014), studies to clarify lipid metabolism in erythroid cells and
how it is affected by glucocorticoid receptor agonists are scanty.
The “research question” of this study was to clarify the
effects exerted by lipid supplements during all the stages of
erythroid maturation from progenitor cells down to mature
cells using multiple end-points. The aim of this question was
to formulate a culture media containing lipid supplements
designed for erythroid cells. We hypothesized that the use
of this media would allow generating greater numbers of
human erythroblasts in proliferation culture. These erythroblasts
would also have greater potential for terminal maturation. To
address this research question, we first compared the expression
profiling of erythroblasts generated with and without Dex.
Next we evaluated the morphology of the plasma membranes
and of the mitochondria of proerythroblasts generated with
Dex and lastly we performed a comprehensive analysis of the
effects exerted by various lipid supplements on the number
and quality of the erythroid cells generated in culture. The
results obtained indicate that Dex impairs the metabolism
and membrane homeostasis of the erythroblasts making their
expansion and maturation exquisitely dependent from lipids
uptake from exogenous sources.
MATERIALS AND METHODS
Human Specimens and Cell Preparation
Plasma and buffy-coats from whole blood donations were
discarded material provided from Centro Trasfusionale,
University of La Sapienza to be used in experiments performed
at Istituto Superiore Sanità. The consent form of the Centro
Trasfusionale includes consent to the use of the donation for
research. Since specimens were provided as de-identified
material, the study was considered non-human subject
research by the ethical committee of Istituto Superiore
Sanità. Buffy-coats were subjected to mononuclear cell
(MNC) separation by Ficoll-Paque (Sigma, St. Louis, MO,
United States) centrifugation, cryopreserved in Iscove’s modified
Dulbecco’s medium (IMDM, Gibco-Invitrogen, Carlsbad, CA,
United States), FBS (50% vol/vol, Sigma) and dimethylsulphoxide
(10% vol/vol, Sigma) and stored in liquid nitrogen.
Purification of Lipoproteins From Human
Plasma
Plasma pools of normolipidemic donors were separated into
total (TL), high-density (HDL), low-density (LDL) and very
low-density (VLDL) lipoprotein fractions by flotation in a
series of three centrifugations in which the density (ρ) of
the plasma was progressively increased by adding powder
KBr according to the procedure established by Havel et al.
(1955) (Supplementary Figure S1A). The amount of KBr to be
added was calculated using the Radding and Steinberg formula
(Radding and Steinberg, 1960):
XKBr =
V× (ρf − ρi)
1− 0.312× ρf
where:
XKBr = amount of KBr in grams
V = volume of plasma sample in mL
ρf = final (desired) density to which the solution is to be adjusted
ρi = initial density of the solution to be adjusted
the numerical factor 0.312 = partial specific volume of KBr.
Briefly, plasma was divided into two aliquots, one of which
was brought to ρ = 1.21g/mL, then centrifuged. The top
fraction, containing TL, was collected while the bottom one
discarded. The second plasma aliquot was centrifuged without
addition of KBr. In this case, the top fraction, containing
the VLDL, was stored while the bottom one was brought to
ρ = 1.063 g/mL and centrifuged again. The top fraction of
this second centrifugation, containing the LDL, was stored
while the bottom one was brought to ρ = 1.21 g/mL and
centrifuged again. The top fraction of this third centrifugation,
containing the HDL, was stored while the bottom one was
discarded. All centrifugations were performed at 40,000 rpm
(Beckman L-70 ultracentrifuge, 60-TI rotor), at 8◦C for 18 h.
The fractions were made tissue culture grade by two sequential
dialyses, one against H2O (to remove KBr) and the other
one against Iscove Modified Dulbecco’s Medium (IMDM) (to
balance their osmolarity), sterilized by filtration through a
0.45 µm filter and stored at −20◦C. Possible lipid and protein
losses induced by the dialysis and filtration processes were
documented by determining the protein and lipid content
of the tissue culture grade fractions. Quantitative analysis of
the apolipoprotein composition of the individual lipoprotein
fractions was performed by gel electrophoresis followed by
Coomassie or Silver staining (Thermo Scientific, Rockford, IL,
United States) (Supplementary Figure S1B) and densitometric
scanning (Supplementary Figure S1C) (Chapman, 1986).
Cholesterol and triglycerides were determined by commercially
available enzymatic assays (cat. R1120 and R1373, BPC BioSed srl,
Castelnuovo di Porto, Italy). The extent of loss was calculated by
comparing the apoprotein/lipid enrichment ratio of each fraction
with that reported in the literature (Supplementary Table S2)
(Chapman, 1986). Although, as predicted, the composition of
the tissue culture grade fractions is significantly different from
that predicted by the literature, some specificity in protein
and lipid composition was observed. In particular, Fraction 1
(i.e., purified VLDL) is rich in Apolipoprotein (Apo) B100, A1
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and C1-3 and expresses a cholesterol/triglyceride ratio of 0.36.
Fraction 2 (purified LDL) contains ApoB100 with traces of A1,
A2, and C2-3, shows a protein/lipid ratio of 4.5 and contains
approximately three times more cholesterol than triglycerides
(cholesterol/triglycerides ratios = 2.83). Fraction 3 (purified
HDL) contains ApoB100, A4, A1, A2, C1 and traces of E and
human serum albumin (HSA). The cholesterol/triglycerid ratio
of this fraction is similar to that of Fraction 2 (2.5 vs. 2.8).
Ex vivo Expansion of Human
Erythroblasts
MNC (106 cells/mL) were cultured under human erythroid
massive amplification (HEMA) conditions in the presence
of human SCF (10 ng/mL, Amgen, Thousand Oaks,
CA, United States), EPO (3 U/mL, Janssen, Raritan, NJ,
United States), IL-3 (1 ng/mL, PeproTech, Rocky Hill, NJ,
United States), Dex and estradiol (both 10−6M, Sigma
Aldrich, Saint Luis, MO, United States). The culture media
was represented by IMDM supplemented with either FBS
(HEMAser) (Migliaccio et al., 2002), or clinical grade components
mostly of human origin (HEMAdef) (Migliaccio et al., 2010)
(Supplementary Figure S2). The components of HEMAdef are
deionized HSA (10% v/v, Baxter International Inc., Deerfield,
IL, United States), human iron saturated transferrin (TRF),
recombinant human insulin (Merck KGaA, Darmstadt,
Germany), β-mercaptoethanol, sodium pyruvate, nucleosides,
trace elements and L-glutamine (all from Sigma-Aldrich).
Sources of lipids were represented by either home-made (HM)
liposomes composed by HSA, cholesterol (400 µg/mL, Cat.
No. C3045, Sigma-Aldrich) and soybean lecithin (1.2 mg/mL,
Cat. No. P3644, Sigma-Aldrich), or culture-grade lipids
from commercial sources or lipoprotein fractions purified
from human plasma described above. The commercial lipids
investigated were: A: Lipids Cholesterol Rich from adult bovine
serum (Cat. L-4646); B: Fatty Acid Supplement (Cat F7050);
C: Lipid Mixture (Cat. L-0288) (all from Sigma-Aldrich), D:
Chemically defined Lipid Concentrate (Cat. 11905-031, Gibco
Invitrogen, Carlsbad, CA, United States) and E: commercial
tissue culture grade LDL (Cat. LP2-2MG, Sigma). LDL-Sigma
contain more lipids (78–80% vs. 18%) but less proteins (22–20%
vs. 82%) than HM-LDL (Supplementary Table S3). Cultures
were incubated at 37◦C in a fully humidified 5% CO2 atmosphere
and the cells analyzed every 2–4 days up to days 18 of culture.
A list of the end-points analyzed in this study and their biological
implications is provided in Supplementary Table S1.
Determinations of Cell Numbers, Viability
and Phenotype
Cell numbers and viability were determined by microscopic
evaluation of cells stained with trypan blue (Boston Bioproducts,
Ashland, MA, United States) in a Burker chamber. The
maturation state was assessed by flow cytometry on the basis
of CD235a (glycophorin A) and CD36 (the thrombospondin
receptor) expression using the phycoerythrin (PE)–conjugated
CD36 and allophycocyanin (APC)-conjugated CD235a
antibodies, or appropriate isotype controls (all from
BD-Pharmigen, San Diego, CA, United States) (Migliaccio
et al., 2011). Maturation stages were confirmed by visual
examination of cytocentrifuged smears (Cytospin 3, Shandon,
Astmoor, United Kingdom) (Chapman, 1986). Dead cells
were excluded by Sytox Blue staining (0.002 mM, Molecular
Probes). Fluorescence was measured with a FACS Aria and
data were analyzed with the FlowJo software (Tree Star,
Inc., Ashland, OR, United States). Sensitivity to autophagic
death was determined by Acridine Orange (AO) staining
(Fluka Biochemika, Buchs, Switzerland), as described
(Migliaccio et al., 2011).
Colony Forming Assay
MNC (105 cells/plate) were cultured in semisolid media
under conditions resembling either HEMAser or HEMAdef (cf.
previous sections). HEMAser cultures were represented by a
commercial semisolid methylcellulose assay containing FBS
(30% v/v, MethoCult Stem Cell Technology, Inc., Vancouver, BC,
Canada). HEMAdef cultures were represented by a home-made
methylcellulose assay in which FBS is replaced by deionized
human serum albumin (HSA) and HSA-adsorbed cholesterol
(final concentrations, 2 × 10−4 mol/L), iron-saturated
transferrin (5 × 10−7 mol/L), insulin (1.7 × 10−6 mol/L),
nucleosides (10 µg/mL each), sodium pyruvate (10−6 mol/L)
and L-glutamine (2 × 10−3 mol/L), as previously described
(Migliaccio and Migliaccio, 1987). All the cultures were
stimulated with human SCF (100 ng/mL), IL-3 (10 ng/mL),
GM-CSF (10 ng/mL), G-CSF (100 ng/mL) and EPO (5 U/ml), as
described (Masiello et al., 2013). Plates were incubated at 37◦C
in a fully humidified incubator containing 5% CO2. Colonies
were scored after 8 (colony forming unit-granulocytic erythroid,
CFU-E) and 14 (burst forming unit-erythroid, BFU-E, colony
forming unit-granulo-monocytic, CFU-GM and colony forming
unit-granulocyte, eythroid, megakaryocyte and monocyte,
CFU-GEMM) days according to standard morphological criteria
(Masiello et al., 2013).
Proliferation Assay
Cell proliferation was assessed by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as
described (Falchi et al., 2015) where the MTT assay was
validated as an index of erythroblast proliferation by
careful correlations between MTT values and increased cells
numbers detected by visual cell counting. Briefly erythroblasts
(5 × 105cells/100 µL/well) were plated in triplicate wells of a
96-well microtitre flat-bottomed plate in the absence or presence
of increasing concentrations of commercially available lipid
supplements or individual lipoprotein fractions and cultured
for 72 h at 37◦C in a humidified incubator with 5% CO2 in air.
Ten µL of MTT [5mg/mL] were then added to each well and
incubated at 37◦C in a humidified atmosphere for additional
4hrs. The solution was removed and the resulting formazan salts
dissolved with Sorensen’s Glycine Buffer (0.1M Glycine plus
0.1M NaCl in PBS). Optical densities were measured at 540 nm
in the VICTOR3TM microplate reader (Perkin Elmer, Waltham,
MA, United States) and expressed as absorbance (ABS) values.
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Expression Profiling by Microarray
Analyses
The expression profile of human erythroblasts generated at
days 10 in HEMAser with or without Dex was previously
published (Hricik et al., 2013). The list of differentially
expressed genes was manually searched for those involved in
lipid metabolism.
Statistical Analysis
Results are presented as Mean (±SD) of at least three
separate experiments, unless stated otherwise. Statistical
analysis was performed by paired t-test and ANOVA (Origin
6.0 for Windows, Microcal Software, Inc., Northampton,
MA, United States) and considered statistically different
with a p < 0.05.
RESULTS
The Expression Profiling of Erythroblasts
Generated in the Presence of Dex
Predicts Altered Lipid Metabolism
Given the great role played by glucocorticoids in the development
of fatty liver disease (Woods et al., 2015), most of what is
known on the effects of these hormones on lipid metabolism
has been obtained in liver using holistic experimental models.
These studies have indicated that glucocorticoids promote the
availability of cholesterol indirectly, by increasing the production
of VLDL by liver cells, and that of triglycerids directly, by
promoting their ex novo synthesis by the cells (Bagdade et al.,
1976). By contrast, there is little information on the role
played by glucocorticoids in the control of lipid metabolism in
erythroid cells.
To clarify the genes targeted by Dex in erythroid cells,
in a previous study we compared the expression profiling
of erythroblasts generated by days 10 in HEMAser with and
without Dex (Hricik et al., 2013). We chose days 10 because
this time point contained great numbers of erythroblasts in the
process of switching from a proliferation to a maturation mode
(Migliaccio et al., 2011), allowing us to detect targets affecting
both processes. This study has revealed that erythroblasts
generated with and without Dex differ in the expression of only 55
genes (Hricik et al., 2013). By manual analyses, we discovered that
six of the differentially expressed genes (approximately 10%) are
involved in lipid metabolism, three of which at the mitochondria
level (Table 1).
Dex activates and inhibits, respectively, the expression
of HMGCL and OXCT1, which are synergistically involved
in the terminal stages of lipid degradation and in the
ketogenic pathway in mitochondria (Fu et al., 2010; Fukao
et al., 2014), and increases the expression of ABCA1, which
encodes a cholesterol efflux pump (Litvinov et al., 2018).
Dex also activates HSD17B7, which encodes an enzyme
of the cholesterol biosynthetic pathway (Marijanovic et al.,
2003), and decreases the expression of PRKACB, the signaling
mediator of several metabolic processes, and of GPAM,
the gene that codes for rate-limiting enzyme (GPAT1) of
the glycerolipid biosynthetic pathway (Wendel et al., 2009;
Søberg and Skålhegg, 2018).
These results suggest that Dex impairs the overall
cell metabolism, including lipid metabolism, making the
membrane homeostasis of these cells, and possibly additional
functions, particularly dependent on lipids up taken from
exogenous sources.
Numerous Erythroblasts Generated in
the Presence of Dex Present
Morphological Evidence of Plasma
Membrane and Mitochondria Fragility
To assess whether possible impairment of lipid metabolism
may affect the quality of the plasma membrane, we first
compared by optical microscopy the morphology of erythroblasts
generated by days 10 in the presence and absence of Dex
(Figure 1A and results not shown). These observations revealed
TABLE 1 | Genes encoding proteins controlling lipid metabolism that are differentially expressed on erythroid cells obtained from adult sources in cultures stimulated with
and without Dex.
Gene symbol Fold Change p-value Name Function
Effects of Dex Activation HMGCL +1.55 2.15E-0.5 3-Hydroxymethyl-3-Methylglutaryl-CoA
Lyase
Mitochondrial enzyme involved in the
ketogenic pathway
ABCA1 +2.18 1.71E-0.5 ATP-binding cassette, sub-family A,
member 1
Mediator of cholesterol efflux
HSD17B7 +1.49 1.55E-0.5 Hydroxysteroid 17-Beta
Dehydrogenase 7
Postsqualene Enzyme of Cholesterol
Biosynthesis
Inhibition OXCT1 −1.51 4.50E-0.5 3-Oxoacid CoA-Transferase 1 Mitochondrial enzyme involved in the
ketogenic pathway
GPAM −1.38 2.03E-0.5 Glycerol-3 Phosphate Acyltransferase,
Mitochondrial
Rate limiting enzyme of triacylglycerol
biosynthesis
PRKACB −1.14 6.19E-0.5 Protein Kinase CAMP-Activated
Catalytic Subunit Beta
Mediator of cAMP signaling in several
metabolic processes, including in the
regulation of lipid metabolism
Symbols of the genes activated (positive fold change) and inhibited (negative fold change) by Dex.
Frontiers in Physiology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 281
fphys-10-00281 April 2, 2019 Time: 19:56 # 6
Zingariello et al. Lipid Metabolism in Erythroid Cells
FIGURE 1 | Ex vivo generated erythroblasts present morphological evidence of plasma and mitochondrial membrane damage. (A) The erythroblasts plasma
membrane presents numerous pebbles. May-Grunwald-staining of representative cytospin preparations of erythroblasts from days 10 HEMAdef culture obtained with
and without Dex, as indicated. Representative pro-erythroblasts are shown at higher magnifications in the inserts. Original magnification 40X. (B,C) The membrane
pebbles present ultrastructural features associated with exosome and micro-particle release. Electron microscopy analyses of the pebbles on the plasma membrane
of representative pro-erythroblasts from days 10 HEMAdef with Dex. (B) At greater magnification, the pebble, probably a multivesicular body, shows eruption of the
plasma membrane with extrusion of exosomes and free ribosomes (red arrows). (C) At greater magnification, the pebble shows the presence of membrane leaking
(red arrows) and release of micro-particles (panel of the bottom). Greater magnification of this pro-erythroblast (panel on the top) also shows the localization of the
mitochondria at a pole of the cytoplasm, the mitochondria body. In addition, the mitochondria present morphological sign of distress (red circle) while the cisterns of
the surrounding rough endoplasmic reticulum present numerous traits deprived of ribosomes (blue arrows). (D) The mitochondria from erythroblasts cultured with
Dex present several abnormalities of the crest membranes. Electron microscopic analyses of a representative pro-erythroblast showing at greater magnification that
the mitochondria present several crest abnormalities (reduction in number, diameter larger than normal and membrane ruptures). Only the most external
mitochondria (yellow circle) appears partially fused with a phagosome (yellow arrow, bottom left panel). The panel on the right shows fusion among mitochondria
(blue circle). Red asterisks indicate centrioles and green asterisks autophagy vesicles. Original magnifications are indicated below each panel.
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that cultures with Dex contain greater numbers of erythroid
cells presenting alterations of their membrane resembling
protrusions or pebbles than those without Dex. In the
case the pro-erythroblasts, easily recognizable on smears by
their typical morphology and larger size (>30 µm) (Insert
in Figure 1A), the frequency of cells presenting pebbles
was 14 ± 5% in HEMAser and 23 ± 7% in HEMAdef
(p < 0.05), respectively.
The fine structure of the membrane abnormalities was defined
by electron microscopy analysis of erythroblasts expanded
in HEMAdef, a condition considered superior for generating
cRBCs because it sustains levels of amplification 10-times
greater than HEMAser (Migliaccio et al., 2010). Also this analysis
was focused on cells with the ultrastructural characteristics of
pro-erythroblasts obtained at days 10 of culture. These studies
provided evidence that the membrane pebbles are associated
with two different types of ultrastructural abnormalities.
The first abnormality resembles a burst bubble of plasma
membrane with leakage of intracytoplasmic material, as well
as of exosomes (<20 nm in diameter) in the environment, a
clear indication of membrane fragility, that possibly originated
from nearby multivesicular bodies (Raposo and Stoorvogel,
2013) (Figure 1B). The second abnormality resembles
micro-vesicles ranging in diameter from 105 to 3500 nm
(with an average of 1410 ± 877 nm) being released in the
environment (Figure 1C).
These results indicate that pro-erythroblasts generated with
Dex are prone to express membrane abnormalities leading to
exosome and microvesicle release, a feature that in RBCs has been
reported associated with conditions of cellular distress (Raposo
and Stoorvogel, 2013; Leal et al., 2018).
Electron microscopy analysis also allowed us to monitor
the plasma membrane of the mitochondria (Figures 1C,D). In
pro-erythroblasts, mitochondria are localized at a pole of the
cytoplasm forming a structure that we define mitochondrial body
(top panel in Figure 1C). Most, if not all, of the mitochondria
are abnormal in morphology with reduced and enlarged internal
crests (top panel in Figures 1C,D). Only a minority of them,
mostly those located in the periphery of the mitochondrial body,
appears engulfed into autophagic vesiscles in preparation of the
mitophagic degradation that leads to formation of reticulocytes
(Moras et al., 2017).
These results provide morphological evidence suggesting that,
during erythroid maturation, mitochondria lose their metabolic
functions, including those involved in lipid biosynthesis, at the
pro-erythroblast stage before the formation of the mitophagic
vesicles required for terminal maturation and that these processes
may be affected by Dex.
Commercial Lipid Supplements and
Lipoproteins Purified From Human
Plasma Improve Short-Term Proliferation
of Human Erythroblasts in Culture
The morphological data presented above (Figure 1) suggest that
the plasma membrane abnormalities of erythroblasts generated
under current culture conditions are possibly influenced by
insufficient and/or not appropriate lipid supplementation in
the culture media.
To begin assessing the role exerted by lipid supplementation
on ex vivo erythroblast expansion, we first determined the
level of short-term proliferation of these cells under HEMAser
and HEMAdef conditions supplemented either with lipid
formulations commercially available or with lipoprotein fractions
purified from human plasma (Figure 2).
Both under HEMAser and HEMAdef conditions, commercially
available supplements sustain levels of proliferation similar
(chemically defined lipid concentrate from Gibco), or
greatly inferior (see the toxicity exerted by the Fatty Acid
Supplement cat L-0288 from Sigma), to those observed
in controls (Figure 2A). By contrast, all the lipoprotein
fractions (regardless of the concentration used) sustain levels
of erythroblast proliferation similar to controls in HEMAser,
which already contain bovine lipoproteins provided by FBS
(Figure 2B). Of note, TL, HDL and VLDL sustain erythroblast
proliferation similar to control in HEMAdef, that does not
contain any additional lipid supplement while LDL significantly
increases erythroblast proliferation with respect to controls in a
concentration dependent fashion with maximal effects observed
at 20–40 µg/mL.
These results indicate that while none of the commercially
available lipid supplements is capable to improve proliferation
of human erythroblasts above controls, the lipoproteins purified
from human plasma, and in particular LDL, which is the
fraction with the greatest protein content (Supplementary
Table S2), may represent a better source of lipids than HM
liposomes in HEMAdef.
LDL Increases the Number of
BFU-E-Derived Colonies Generated in
Semisolid Media Under Both HEMAdef
and HEMAdef Conditions
To start assessing the effect of lipid supplementation on
erythroid differentiation, we first enumerated the number
of hematopoietic colonies generated in semisolid assay
by MNC from normal blood donors under HEMAser and
HEMAdef conditions supplemented with lipoproteins purified
from human plasma (Table 2). In these, as well in all the
other experiments described from now on, lipoprotein
fractions were tested at a concentration of 20 µg/mL.
These experiments tested also commercially available
LDL for comparison.
Both TL in HEMAser and all the lipoprotein fractions in
HEMAdef have modest, although significant, effects on the
growth of CFU-GM-derived colonies while do not improve the
growth of GFU-GEMM-derived colonies (Table 2). By contrast,
LDL (by 30%) and VLDL (by approximately 100%) significantly
increase the numbers of BFU-E-derived colonies generated in
HEMAser (78 ± 8 and 112 ± 15 vs. 57 ± 9, p < 0.01) while
LDL increase (by 1.5-fold) that of BFU-E-derived colonies in
HEMAdef (64 ± 8 vs. 38 ± 5, p < 0.05). To be noted that the
commercial LDL does not improve colony growth neither in
HEMAser not in HEMAdef.
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FIGURE 2 | Plasma lipoproteins increase short-term proliferation of human erythroblasts in HEMAdef. (A) MTT proliferation assay of days 6 erythroblasts cultured for
4 days under HEMAser (left panel) or HEMAdef (right panel) conditions in the presence of commercially available lipid preparations. Source of lipids: (A) Lipids
Cholesterol Rich from adult bovine serum (Cat. L-4646, Sigma-Aldrich); (B) Fatty Acid Supplement (Cat. F7050, Sigma-Aldrich); (C) Lipid Mixture (Cat. L-0288,
Sigma-Aldrich) and (D) Chemically defined Lipid Concentrate (Cat. 11905, Gibco). In control cultures, the source of lipids was FBS (HEMAser) or home-made
liposomes (HM, HEMAdef) designed to achieve maximal erythroblast amplification in chemically defined culture conditions (31) (see Materials and Methods for further
details). Results are expressed as absorbance (ABS) at 540 nm and are presented as Mean (±SD) of three experiments performed in triplicate, each one with a
different donor. Results statistically different from the corresponding controls (p ≤ 0.01, by paired t test) are indicated by ∗. (B) MTT proliferation assay of days 6
erythroblasts cultured for 4 days in the presence of increasing concentrations of lipoproteins purified from human plasma as described in Supplementary
Figure S1. Controls were represented either by FBS (HEMAser) or home-made liposomes (HEMAdef) and are indicated by the gray areas. Results are presented as
Mean (±SD) of three experiments performed in triplicate. In HEMAdef, results obtained with LDL are statistically different from the corresponding controls with
p ≤ 0.05 (∗) at 10 µg/mL and p ≤ 0.01 (∗∗) at 20 and 40 µg/mL (by paired t test).
These results indicate that the LDL (and to some extent VLDL)
fraction purified from human plasma increases the number of
BFU-E induced to form erythroid colonies in semisolid cultures.
Both LDL and VLDL Increased the
Number of Erythroblasts Generated in
Liquid Culture by Adult MNC Under
HEMAdef Conditions
To further explore in some detail the effects exerted by
the lipoprotein fractions, we also evaluated the levels of
erythroblast expansion in liquid culture supplemented with
these preparations (Figure 3). In HEMAser, the various
lipoprotein fractions investigated do not improve the overall
fold increase (fold-increase ∼20–40 by days 14–17 in the
presence of all supplements). By contrast, both LDL and
VLDL increase by 3-fold the total number of erythroblasts
generated by days 14–17 under HEMAdef conditions (Fold
Increase 95 ± 10 and 64 ± 14 vs. 27 ± 6, p < 0.01–0.05,
respectively for LDL and VLDL compared to control value
at the same time point) (Figure 3 and Table 3). On
note, the commercial LDL generates erythroblasts in numbers
similar to controls.
Both LDL and VLDL Increase the
Expansion of Erythroid Progenitors in
HEMAdef
To clarify the mechanisms underlying the increased erythroblast
expansion observed in HEMAdef supplemented with LDL and
VLDL, we evaluated the effect exerted over time by the
various lipoprotein supplements on the number of hematopoietic
progenitor cells in liquid culture. Hematopoietic progenitor cells
were determined by culturing aliquots harvested from the liquid
cultures at days 3, 5, 7, 10, and 14 under semisolid conditions and
then scoring the number and type of colonies generated by these
cell aliquots (Figure 4).
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TABLE 2 | Effects of lipoproteins purified from human plasma on the number of colonies generated by human MNC in semisolid cultures under HEMAser and
HEMAdef conditions.
HEMAser BFU-E CFU-GM CFU-GEMM Total
Control 57 ± 9 22 ± 12 0.5 ± 0.4 79 ± 19
16 ± 9
P ≤ 0.05
TL 64 ± 15 0.1 ± 0.3 80 ± 21
HDL 47 ± 17 17 ± 5 0.1 ± 0.3 61 ± 20
78 ± 8
p ≤ 0.01
LDL 25 ± 12 0.3 ± 0.5 104 ± 19 p ≤ 0.01
112 ± 15
p ≤ 0.01
VLDL 29 ± 21 0.3 ± 0.3 142 ± 30 p ≤ 0.01
LDL Sigma 61 ± 10 20 ± 15 0 81 ± 23
HEMA def BFU-E CFU-GM CFU-GEMM Total
Control 38 ± 5 16 ± 6 0.8 ± 0.6 55 ± 9
19 ± 8
p ≤ 0.05
TL 40 ± 3 0.7 ± 0. 6 60 ± 11
17 ± 8
p ≤ 0.05





LDL 1.2 ± 0.8 83 ± 12 p ≤ 0.05
18 ± 7
p ≤ 0.05
VLDL 48 ± 9 0.5 ± 0.4 67 ± 15
18 ± 8
p ≤ 0.05
LDL Sigma 43 ± 5 0.2 ± 0.2 60 ± 13
Commercially available LDL were analyzed for comparison. Results are presented as number of colonies per 105 MNC and are expressed as Mean (±SD) of at least three
separate experiments performed in duplicate. Values statistically different from controls are indicated by oval circles.
FIGURE 3 | LDL and VLDL significantly increase the numbers of erythroblasts generated in HEMAdef. Total number of cells, expressed as Fold Increase (FI),
generated over time in HEMAser (left) and HEMAdef (right) supplemented with lipoproteins purified from human plasma (TL, red; HDL, green; LDL, pink; VLDL, blue,
all at 20 µg/mL). Results are compared with those obtained with FBS alone (HEMAser), home-made liposomes (HEMAdef) (controls, black) or LDL from a commercial
source (Cat. L-0288 from Sigma, yellow). Results are presented as Mean (±SD) of four experiments each one with a different donor. In HEMAser, the experimental
points are not statistically different from controls. In HEMAdef, LDL at days 14 (p = 0.008) and days 17 (p = 0.013) and VLDL at days 14 (p = 0.004) and days 17
(p = 0.029) are statistically different from the corresponding controls. Commercial LDL is statically different only at days 3 (p = 0.012).
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Fold Increase BFU-E/105 MNC∗∗ Tot CFU/Culture (x103) ABS 540nm (x102)
HEMAser HEMAdef HEMAser HEMAdef HEMAser HEMAdef HEMAser HEMAdef
Control 20 ± 14 27 ± 6 57 ± 9 38 ± 5 n.d. 542 ± 54 3.0 ± 1.4 7.3 ± 6.7
TL 21 ± 13 40 ± 12 64 ± 15 40 ± 3 n.d. 764 ± 216 1.5 ± 0.7 4.5 ± 3.2
HDL 14 ± 12 28 ± 10 47 ± 17 33 ± 3 n.d. 620 ± 100 1.7 ± 0.4 2.1 ± 0.5






n.d. 756 ± 104
p ≤ 0.01
3.7 ± 1.2 17.1 ± 12.1
p ≤ 0.05




48 ± 9 n.d. 1064 ± 292
p ≤ 0.05
4.5 ± 1.3 6.1 ± 2.2
LDL Sigma 23 ± 11 38 ± 9 61 ± 10 43 ± 5 n.d. 680 ± 84 n.d. 7.9 ± 4.4
Results are presented as Mean (±SD) of three experiments performed in triplicate. Experiments were performed in parallel analyzing the same donor under HEMAser and
HEMAdef conditions (three separate donors per experimental point). Total colony forming units, CFU total number of colonies generated in semisolid cultures (see Table 2
and Figures 2–4, 6 for further detail).
FIGURE 4 | LDL and VLDL increase the expansion of erythroid progenitors under HEMAdef conditions. Number of progenitor cells able to generate erythroid (BFU-E
and CFU-E) and myeloid (CFU-GM) colonies present over time in HEMAdef supplemented with either home-made liposomes (HM) or with TL, HDL, LDL or VLDL (all
at 20 µg/mL). Results are expressed as number of progenitor cells per culture and are presented as Mean (±SD) of four experiments each one with a different donor.
See legend of Figure 2 for further detail. Values statistically different (p < 0.05 by paired t-test) with respect to the corresponding data obtained with HM are
indicated by ∗. Values obtained with LDL-Sigma are not statistically different neither from those obtained with HM nor from those observed with LDL.
In cultures supplemented with HM liposomes, the
number of BFU-E and CFU-E progressively increases and
then declines reaching the maximum by days 7. In these
cultures, BFU-E are barely detectable by days 12. In cultures
supplemented with TL and HDL and with commercial LDL,
the number of erythroid progenitors increases over time with
amplitude and kinetics similar to that observed in controls.
By contrast, in cultures supplemented with LDL and VLDL,
the maximal levels of amplification of progenitor cells of
all types is significantly greater than in controls and the
numbers of CFU-E (and CFU-GM) reach their peak at days 10
instead than at days 7.
These results suggest that improved and prolonged expansion
of hematopoietic progenitor cells contributes to the greater
numbers of erythroblasts observed in HEMAdef supplemented
with LDL and VLDL.
Erythroblasts Generated in the Presence
of VLDL Are Resistant to Death by
Autophagy Induced by Growth Factor
Deprivation (GFD)
One of the factors limiting erythroblast expansion in HEMA
is represented by the great number of cells that die by
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autophagy at the end stage of the culture (Migliaccio et al.,
2011). To further investigate the mechanism that underlay
the improved erythroblast expansion observed in the presence
of selected lipid supplements, we assessed the susceptibility
to death of erythroblasts generated ex vivo in HEMAdef
supplemented with HM liposomes or with VLDL. Sensitivity to
death was determined using as surrogate marker the frequency
of erythroblasts undergoing autophagy [identified by Acrydin
Orange (AO) staining] following 4 h of GFD, as described
(Migliaccio et al., 2011).
A great number (23%) of erythroblasts generated in the
presence of HM liposomes became positive to AO staining after
GFD (Figure 5). By contrast, only 2% of erythroblasts generated
with VLDL became AO positive after GFD, an indication
that they are resistant to GFD-induced death. Interestingly,
the cytoplasm of erythroblasts generated with VLDL also
contain fewer vacuoles and their plasma membranes contain
less pebbles than erythroblasts generated with HM (14 ± 6
vs. 23 ± 7, p < 0.05) (see also the morphological analyses
presented in Figure 5).
All the Lipoprotein Fractions From
Human Plasma Increase the Level of
Terminal Erythroid Maturation Observed
by Days 17 in HEMAdef
In spite of the presence of Dex, erythroblasts in the proliferation
phase eventually progress to terminal maturation. Therefore,
to assess the effects of lipid supplementation on the efficiency
of terminal erythroid maturation, the maturation profile
expressed by erythroblasts generated over time under HEMAser
and HEMAdef supplemented with the various lipoprotein
fractions was assessed (Figure 6). These studies exploited the
fact that profiling for CD36/CD235a expression divides human
erythroblasts into three maturation classes corresponding
respectively to pro-erythroblasts (CD36posCD235aneg
cells); basophilic-erythroblasts (CD36posCD235ahigh cells);
and poly-chromatophilic/orthochromatic erythroblasts
(CD36negCD235ahigh cells) (Falchi et al., 2015). The transition
from basophilic- to ortho-erythroblasts is also associated with a
dramatic reduction in size (from 24 to 19 µm) recognizable by
forward/side scatter analyses.
According to our results, in HEMAser, the cells progress
along the maturation pathway with the same kinetics irrespective
of the lipids used as supplement (Figure 6A and results not
shown). Mature erythroblasts (CD36posCD235ahigh) represent
approximately 12–16% of the population by days 7 while all the
erythroblasts express the mature CD36negCD235ahigh phenotype
by days 17. By days 17, the frequency of non-erythroid cells
in HEMAser is high (46%). Since non-erythroid cells do not
proliferate in HEMA (Migliaccio et al., 2002), the relative increase
of this population over time is a further indication of the
great rates of death of erythroblasts at the end stage of HEMA
(Migliaccio et al., 2011). The addition to HEMAser of any of
the lipoprotein fractions tested in this study does not affect the
kinetics of the maturation process but increases the frequency
of mature erythroblasts, which reaches 30-50% by days 17, an
FIGURE 5 | Erythroblasts generated in the presence of VLDL are resistant to
autophagic death induced by growth factor deprivation. The panels on the left
present the flow cytometry and morphological analyses of erythroblasts
generated by days 10 in HEMAdef supplemented either with HM liposomes or
with VLDL (20 µL/mL). The panels on the right compare the frequency of
Acrydine Orange (AO) positive cells, as indication of autophagic death, of the
two populations when cultured for 4 h with (Control) or without growth factors
(growth factor deprived, GFD). Results are representative of those obtained in
two separate experiments.
indication that the presence of lipoproteins increases survival of
mature erythroblasts.
The kinetics of erythroblast maturation in HEMAdef is visible
different than that observed in HEMAser (Figure 6B and results
not shown). In control cultures, immature CD36posCD235aneg
erythroblasts are detected with a frequency (30%) significantly
greater than that observed in HEMAser (12%) by days 7 and
the majority of the cells remains immature until days 17 when
this population still represents 70% of the cells. Conversely,
by days 17 mature erythroblasts represent only 27% of the
cells. A great difference between HEMAser and HEMAdef is
represented by the frequency of non-erythroid cells which are
barely detectable in HEMAdef, an indication of better erythroblast
survival. Of note, the replacement of the HM liposomes with the
lipoprotein fractions does not affect the kinetics of erythroblast
maturation but doubles the frequency of mature erythroblasts
detected in HEMAdef by days 17 (40–60% vs. 27%) (Figure 6B
and results not shown).
To further define the maturation stage of erythroid cells
obtained by days 17 in HEMAdef supplemented with HM, TL and
VLDL, the cells in the CD36low/CD235ahigh gate were reanalyzed
for forward scatter (FSC) and side scatter (SSC), two parameters
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FIGURE 6 | All the lipoprotein fractions increase terminal erythroid maturation under HEMAdef conditions. Contour plots for CD36 and CD235a expression obtained
by FACS of erythroblasts generated over time in HEMAser (A) and HEMAdef (B) supplemented with TL and VLDL. Cells obtained with FBS or with HM liposomes
were analyzed as control. Similar results were observed in cultures supplemented with HDL, LDL and LDL-Sigma (results not shown). Analyses for CD36/CD235a
expression identifies five populations corresponding respectively to lymphocytes (CD36negCD235aneg cells, bright green); pro-erythroblasts (CD36posCD235aneg
cells, blue); basophilic-erythroblasts (CD36posCD235ahigh cells, purple); and polychromatophilic/orthochromatic (CD36negCD235ahigh cells, orange) erythroblasts.
The frequencies of pro-erythroblasts, basophilic and poly/orthochromatic erythroblasts are indicated within the quadrants. Results are representative of those
obtained in two separate experiments. (C) Contour plot for forward scatter (FSC) and side scatter (SSC) of the days 17 cells in the CD36low/neg/CD235apos gate of
Figure 6B. The cells were then re-analyzed for CD36/CD235a expression, sorted and stained with May-Grunwald Gimsa. The numbers inside the panels indicate
the frequency of the cells in the different gates. This analysis allows discriminating between erythroid cells at the polychromatophilic and orthochromatic stage. Only
results obtained in the HM, TL, and VLDL group are presented. The results obtained with TL and VLDL are representative of those obtained with HDL, LDL,
and LDL-Sigma.
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which provide indication for size and cytoplasm granularity.
The events in FSClow/SSClow gate were then re-analyzed for
CD36/CD235a expression and sorted for morphological analyses
by May-Grunwald staining (Figure 6C). These analyses indicate
that in all the experimental groups the mature cells are
small in size. However, the mature gate in the HM group
contains mostly polychromatophilic erythroblasts while those
in the TL and VLDL groups contain both polychromatophilic
and orthochromatic erythroblasts in a 50:50 ratio, these
results indicate that lipoproteins improve terminal erythroid
maturation in HEMAdef.
DISCUSSION
The conditions used to generate cRBCs for the first-in-man
transfusion, as HEMAser, contain FBS (Giarratana et al., 2005)
and are not suited to produce cRBCs for multiple transfusions
because it can be predicted that, as observed with other
cellular products produced with FBS (Selvaggi et al., 1997;
Tuschong et al., 2002), will trigger immunological reactions
against bovine proteins when transfused into patients. Therefore,
the formulation of clinical grade conditions depleted of FBS
represents one of the major challenges in designing the
manufacturing process of cRBCs (Migliaccio et al., 2012). To
address this challenge, we formulated HEMAdef, a media in which
FBS is replaced with clinical grade HSA that sustains erythroblast
expansion in proliferation cultures at levels 10-fold greater than
those observed with HEMAser (Migliaccio et al., 2010). However,
an important drawback of HEMAdef is represented by the source
of lipids which is represented by HM liposomes generated by
sonicating clinical grade HSA with egg-derived cholesterol and
soybean lecithin. Given the known intolerance to both products
existing in the human population, HEMAdef may not be indicated
to produce cRBCs for the general population.
To formulate clinically more suited culture conditions, we
determined ex vivo expansion of erythroblasts in HEMAdef
formulated either with commercial lipid supplements or with
HM lipoprotein fractions purified from human plasma. Parallel
experiments were conducted in HEMAser for comparison. Our
results demonstrate that all the commercially available lipid
supplements tested in this study, including LDL from Sigma,
generated erythroblasts in numbers inferior to those sustained
by HM liposomes (Figure 2). By contrast, supplementation of
HEMAdef with either LDL or VLDL purified in house from
fresh human plasma supports the generation of erythroblasts in
numbers significantly greater (2–3-times) than those generated
by HM liposomes (Table 3).
LDL and VLDL fractions increase the numbers of
erythroblasts generated in culture through mechanisms
targeting both the erythroid progenitor and precursor cells
(Table 3). At the progenitor level, they significantly increase
the number of cells recruited to mature (Table 2) and their
expansion in liquid culture (Figure 4). At the precursor level,
they increase proliferation rates (Figure 2) and resistance to
autophagic death (Figure 5). By contrast, all the lipoprotein
fractions tested, including commercial LDL from Sigma,
increased the levels of terminal erythroid maturation observed
at days 17 (Figure 6), suggesting that lipoproteins are the
factors responsible for improving the enucleation rates in
maturation cultures supplemented with human plasma reported
by previous studies (van den Akker et al., 2010; Masiello et al.,
2013). Although enucleation was not formally investigated in
the present manuscript, the observation that cells generated
with LDL and VLDL matured readily into ortho-chromatic
erythroblasts by days 17 (Figure 6) suggests that these cells, by
exhibiting high enucleation rates, represent a better source than
erythroblasts expanded with current culture media to generate
cRBCs in differentiation cultures.
Several events concurred in determining the greater erythroid
output observed in proliferation cultures supplemented with
lipoproteins. The data presented in this paper provide some clue
on the biochemical mechanisms that may underlie some of these
events which are summarized in Figure 7.
By expression profiling, erythroblasts generated with
and without Dex show differences in only 55 genes, six
of which involved in lipid metabolism (Table 1). More
specifically, ABCA1, which encodes a cholesterol efflux pump
FIGURE 7 | Summary of the effects exerted by the lipoprotein fractions
investigated in this study on erythroid differentiation. Recruitment and
expansion in liquid culture of the erythroid progenitor cells was improved by
LDL and LDL/VLDL, respectively, probably by mechanisms targeting cell
metabolism. LDL increased also the proliferation of days 10 proerythroblasts,
probably by mechanisms involving rearrangement of the cytoskeleton. Lastly
the survival and terminal maturation of the proerythroblasts was favored by
LDL and by all the lipoprotein fractions, respectively through mechanisms
involving improvement of membrane homeostasis. All these biological effects
contributed to the greater erythroid expansion observed in HEMAdef
supplemented with lipoproteins, expecially when the lipoproteins were
represented by LDL and VLDL.
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(Litvinov et al., 2018), and HSD17B7, which is involved in
cholesterol biosynthesis (Marijanovic et al., 2003), are activated
in erythroblasts generated with Dex, suggesting that Dex
may promote cholesterol biosynthesis but overall makes
these cells cholesterol deficient because of higher efflux rates.
Furthermore, Dex inhibits expression of GPAM that encodes an
enzyme involved in the synthesis of phosphatidic acid (Wendel
et al., 2009), a precursor of TG, suggesting that Dex impairs
lipid metabolism in erythroid cells making their membrane
biosynthesis highly dependent on lipid absorbed from exogenous
sources. Although this interpretation is in partial contrast to
other experimental systems such as adipocytes (Lee et al., 2018),
the reason of this difference may relay on the specific biological
functions exerted by Dex during stress erythropoiesis where it
allows the production of greater number of cRBCs by inhibiting
terminal maturation and promoting proliferation. In fact, in
addition to promoting self-replication (Migliaccio et al., 2002;
Zhang et al., 2013), Dex may retain erythroblasts in proliferation
by a novel mechanism involving a direct blocking of terminal
erythroid maturation through down-modulation of GPAM and,
consequently, lower content of phosphatidic acid, the signaling
molecule that activates the cytoskeleton rearrangement and the
vesicle trafficking (Ferraz-Nogueira et al., 2014; Nguyen et al.,
2016) required for this process (see Figure 7).
Our data suggest that lipoproteins reduce the susceptibility of
pro-erythroblasts to death induced by growth factor starvation
and facilitate their terminal maturation by improving membrane
homeostasis. In fact, extensive morphological analyses of
erythroblasts generated with Dex indicate that these cells
present severe abnormalities of the plasma and mitochondrial
membranes suggesting that the lipid bioavailability under
current culture conditions is insufficient. The plasma membrane
abnormalities came in the forms of pebbles associated with
exosome and micro-vesicle formation. Release of micro-vesicles
by RBCs involves disturbance of the membrane/cytoskeleton
interaction (Leal et al., 2018) and is triggered by Ca+2 and
protein kinase C activation (Nguyen et al., 2016). The effects
of micro-vesicle release on the life span of RBCs in vivo
are controversial: it may increase, by eliminating hemoglobin
precipitates, the life span of sickle RBCs but may decrease
that of normal RBCs stored for transfusion (D’Alessandro
et al., 2015; Leal et al., 2018). We predict that the membrane
abnormalities presented by cRBCs may contribute to reduce
their life span in vitro and possibly in vivo (Giarratana
et al., 2005). By argument, we infer that these abnormalities
are the direct consequences of cholesterol insufficiency. In
fact, the inhibitory function of scramblase activity exerted
by cholesterol promotes the phospholipid asymmetry of the
membrane that preserves the shape and promotes survival of
the erythrocytes (Arashiki et al., 2016). Therefore, by reducing
the cholesterol content, Dex may increase the scramblase
activity reducing phospholipid asymmetry (and integrity) of the
membranes. Genetic evidences for the importance of cholesterol
for membrane biosynthesis and RBC survival in vivo also exists.
Patients with Smith-Lemli-Opiz syndrome which is associated
with loss of function mutations in the gene encoding cholesterol
biosynthesis DHCR7-7-dehydrocholesterol reductase have low
levels of cholesterol and are anemic (Jira et al., 2003). In addition,
patients with a rare inherited syndrome leading to synthesis
of plant sterols instead than cholesterol experience hemolytic
anemia (Wang et al., 2014).
In the mitochondria, membrane abnormalities were
observed at the level of the crests and are so severe that
predict reduced mitochondrial functions with consequent
impaired cell metabolism. They were presented by the
majority of the mitochondria independently from their
inclusion into autophagic vesicles. Therefore, it is unlikely that
these abnormalities were caused by the lytic enzymes in the
autophagosomes (Betin et al., 2013). Since phosphatidic acid
is also a precursor for cardiolipin, the key phospholipid of the
internal mitochondrial membranes controlling their functional
integrity, bioenergetics and apoptosis (Paradies et al., 2014;
Ikon and Ryan, 2017; Mårtensson et al., 2017), we propose that
the membrane abnormalities of the mitochondria observed in
erythroblasts generated with Dex are due to reduced cardiolipid
content as a consequence of GPAM down-regulation.
Red blood cells express a variety of apolipoprotein receptors,
in primis the receptor for ApoA1 and B as demonstrated by
the hypocholesterolemia and reduced levels of circulating ApoA1
and B expressed by patients with the acquired erythrocytosis
Polycythemia Vera (Fujita et al., 2012). Given the great number
of RBCs present in the circulation, these receptors are efficient
lipid scavengers contributing to maintain the lipid content of
the plasma within physiologic levels preventing atherosclerosis
and kidney malfunctions (Wahl et al., 2016; Saraf et al., 2017;
Vuorio et al., 2018). The effects on erythroblast expansion
sustained by VLDL and LDL described in this study suggests
that, in addition to exerting scavenger functions, the lipoprotein
receptors expressed by erythroid cells tune lipid availability to
prevent possible membrane abnormalities due to impairment
of lipid metabolism induced by Dex in RBCs produced under
conditions of erythroid stress.
The observation that all the lipoprotein fractions promote
terminal maturation while only LDL and VLDL promote
erythroblast expansion suggests that the effects exerted by
lipoproteins on hematopoietic stem/progenitor cells are mediated
by mechanism(s) at least partially different from that exerted
during terminal maturation (regulators of lipid bioavailability).
These mechanism(s) may be represented by improvement of
the overall deficient metabolism caused by Dex (Figure 7)
and/or by still to be identified signaling functions exerted by
specific protein component of LDL and VLDL. Although further
studies are necessary to clarify possible signaling functions of the
individual lipoproteins, recent evidences support this hypothesis
by indicating that lipoproteins control directly the proliferation
of hematopoietic stem/progenitor cells. This proliferation is
inhibited by cholesterol bound-HDL through activation of
ABCA1 (Yvan-Charvet et al., 2010), a gene found by us activated
by Dex (Table 1), while it is promoted by LDL through a
mechanism still to be identified (Yvan-Charvet et al., 2010; Feng
et al., 2012; Seijkens et al., 2014). These observations may explain
why erythroblast expansion is not affected by the presence of
HDL and TL, which contain both HDL and LDL, but it is
promoted by LDL. Further studies are necessary to clarify the
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mediators of the effects of LDL on the proliferation of erythroid
progenitors and how these mediators interact with the control
exerted by HDL/ABCA1 pathway regulated by Dex.
CONCLUSION
Overall, the results discussed in this paper highlight the
importance of further studies on lipid metabolism and
mitochondrial function in erythroblasts and how they are
regulated by Dex to increase our understanding on how to
improve the functions of RBCs generated in vivo under condition
of stress. They also demonstrate a novel beneficial effect of
LDL and VLDL on recruitment and expansion of erythroid
progenitor and precursor cells in the proliferation phase of
HEMAdef, indicating that media formulated with supplements
which include clinical grade VLDL and/or LDL will allow the
generation of greater numbers of cRBCs that will possible survive
longer in vivo for transfusion.
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FIGURE S1 | Characterization of the lipoprotein fractions purified from human
plasma investigated in the study. (A) Diagram of the purification scheme indicating
the series of ultracentrifugations used for lipoprotein fractionation. ρ indicates the
density of the original plasma or of infranates prepared for ultracentrifugation and
is expressed as g/mL. (B) Commassie blue and silver staining of the proteins
contained in the various lipoprotein fractions separated by gel electrophoresis. The
numbers on the top indicate the amount of protein loaded. The position of the
molecular weight markers is indicated in kDa on the left while the identity of the
bands (predicted on the basis of their size) is indicated by arrows with the
corresponding labels (Chapman, 1986). (C) Densitometric profile of the bands
present in the lanes of the gel stained with Silver presented in (B).
FIGURE S2 | Design of the experiments used to evaluate the effects of lipid
supplementation on erythroblasts expansion under HEMAdef and HEMAser
conditions. As summarized in Supplementary Table S1, end-points of these
experiments were represented by expansion of erythroid (liquid cultures, Figure 3)
and progenitor (semisolid cultures, Figure 4) cells over time and short-term
proliferation (Figure 2), ability to progress along the terminal maturation pathway
(Figure 5) and resistance to stress-induced autophagic death (Figure 6).
TABLE S1 | list of the end-points analyzed in our study and of their corresponding
biological implications.
TABLE S2 | Protein and lipid content of the lipoprotein fractions purified from
human plasma used in the study. The expected protein/lipid and CH/TG ratios in
each fraction on the basis of published data.
TABLE S3 | Comparison of the composition of the home made and
Sigma LDL fractions.
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